Jordi Rodon Ahnert

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 20 papers. Top paper: “Phase 2 study of pembrolizumab in patients with advanced rare cancers”.

Phase 2 study of pembrolizumab in patients with advanced rare cancers

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2019-000347

N/A

4.0DataRank · unranked

131 citations

Funda Meric‐Bernstam, Bettzy Stephen, Daniel D. Karp, Joud Hajjar, Jordi Rodon Ahnert +35 more

A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609)

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2182

N/A

3.8DataRank · unranked

125 citations

Megan Othus, Sandip Pravin Patel, Kathy D. Miller, Rashmi Chugh, Scott M. Schuetze +23 more

Preclinical study and parallel phase II trial evaluating antisense STAT3 oligonucleotide and checkpoint blockade for advanced pancreatic, non-small cell lung cancer and mismatch repair-deficient colorectal cancer

BMJ Oncology(2024)10.1136/bmjonc-2023-000133

N/A

0.473DataRank · unranked

13 citations

Genevieve Hartley, Coline Couillault, Ying Yuan, Heather Lin, Courtney Nicholas +18 more

Phase I study of sapanisertib (CB‐228/TAK‐228/MLN0128) in combination with ziv‐aflibercept in patients with advanced solid tumors

Cancer Medicine(2024)10.1002/cam4.6877

N/A

0.418DataRank · unranked

8 citations

Bettzy Stephen, Siqing Fu, Daniel D. Karp, Vivek Subbiah, Jordi Rodon Ahnert +8 more

Phase I/II study of BMS-986156 with ipilimumab or nivolumab with or without stereotactic ablative radiotherapy in patients with advanced solid malignancies

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2024-009975

N/A

0.271DataRank · unranked

4 citations

Xinyan Xu, Girish S. Shroff, Nathan Comeaux, Wei Li, Jordi Rodon Ahnert +7 more

Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences

Scientific Reports(2022)10.1038/s41598-022-12669-5

N/A

0DataRank · unranked

24 citations

Funda Meric‐Bernstam, David S. Hong, Filip Jankú, Aung Naing, Sarina A. Piha‐Paul +13 more

Phase 1/2 trial of avelumab combined with utomilumab (4‐1BB agonist), PF‐04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies

Cancer(2023)10.1002/cncr.35063

N/A

0DataRank · unranked

17 citations

Jibran Ahmed, Bettzy Stephen, Sarina A. Piha‐Paul, Daniel D. Karp, Abdulrazzak Zarifa +13 more

Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer

Scientific Reports(2023)10.1038/s41598-023-46586-y

N/A

0DataRank · unranked

15 citations

Argun Akçakanat, Ming Zhao, Kurt W. Evans, Erkan Yuca, Stephen Scott +11 more

Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple‐negative breast cancer

Cancer(2023)10.1002/cncr.34773

N/A

0DataRank · unranked

5 citations

Sadia Saleem, Senthil Damodaran, Neeta Somaiah, Sarina A. Piha‐Paul, Julia Ann Moore +18 more

Lefitolimod (TLR agonist) and ipilimumab in patients with advanced solid tumors: A phase I trial.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.2564

N/A

0DataRank · unranked

4 citations

Matthew J. Reilley, Amadeo B. Biter, JoAnn Lim, Stacie A. Bean, Ly M. Nguyen +14 more

A phase 2 study of the WEE1 inhibitor AZD1775 in SETD2-deficient advanced solid tumor malignancies.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.3104

N/A

0DataRank · unranked

3 citations

W. Kimryn Rathmell, Geoffrey I. Shapiro, Jordi Rodon Ahnert, Devalingam Mahalingam, Nikolaos A. Trikalinos +9 more

Data from A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609)

(2023)10.1158/1078-0432.c.6530837

N/A

0DataRank · unranked

0 citations

Megan Othus, Sandip Pravin Patel, Kathy D. Miller, Rashmi Chugh, Scott M. Schuetze +23 more

Baseline symptom, health status, and health utilities in patients in early-phase clinical trials combining immune checkpoint blockade with other anticancer therapies.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.12117

N/A

0DataRank · unranked

0 citations

Sarina A. Piha‐Paul, Siqing Fu, Jordi Rodon Ahnert, Timothy A. Yap, Vivek Subbiah +10 more

MTA-cooperative PRMT5 inhibitors enhance T cell-mediated antitumor activity in MTAP-loss tumors

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2024-009600

N/A

0DataRank · unranked

19 citations

Jiakai Hou, Roshni Jaffery, Ashley Guerrero, Rongjie Fu, Leilei Shi +18 more

FGFR3-induced Y158 PARP1 phosphorylation promotes PARP inhibitor resistance via BRG1/MRE11-mediated DNA repair in breast cancer models

Journal of Clinical Investigation(2025)10.1172/jci173757

N/A

0DataRank · unranked

4 citations

Hirohito Yamaguchi, Yuan Gao, Weiya Xia, Jeffrey T. Chang, Yu‐Chun Hsiao +27 more

Phase I study of bevacizumab and temsirolimus combination therapy in advanced malignancies: safety, efficacy, and ovarian cancer expansion

The Oncologist(2025)10.1093/oncolo/oyaf413

N/A

0DataRank · unranked

0 citations

Chieh Tseng, Emily Thompson, R. Jason Stafford, Hung Le, Lei Kang +12 more

Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2020-001752

N/A

0DataRank · unranked

54 citations

Christian Rolfo, Murat Ak, Mira Ayoub, Sara Ahmed, Nabil Elshafeey +13 more

Integrating genome-wide CRISPR immune screen with multi-omic clinical data reveals distinct classes of tumor intrinsic immune regulators

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2020-001819

N/A

0DataRank · unranked

47 citations

Yunfei Wang, Leilei Shi, Yuan Chen, Chunyu Xu, Arash Saeedi +16 more

Author response to Cunha et al

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-003299

N/A

0DataRank · unranked

5 citations

Christian Rolfo, Murat Ak, Mira Ayoub, Sara Ahmed, Nabil Elshafeey +13 more

Patients with advanced solid cancers treated with ERK inhibitors exhibit pseudo-progession in lymphatic nodes.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.3138

N/A

0DataRank · unranked

0 citations

Daniel D. Karp, Abha Adat, Timothy A. Yap, Siqing Fu, Jordi Rodon Ahnert +12 more